Experts warn of health and legal risks as black market demand spikes for experimental jab Retatrutide

Health experts and clinicians have issued urgent warnings after a reported surge in black market interest in Retatrutide, an experimental weight-loss injection that early trial data suggest can produce marked reductions in body weight. The warnings say obtaining the drug outside regulated channels is both medically dangerous and potentially criminal.

Retatrutide, manufactured by Eli Lilly and nicknamed the "Godzilla" or "triple G" of weight-loss jabs because it targets three hormones involved in appetite and weight regulation, has shown in early studies the potential to help people lose about a quarter of their body weight in under a year. Trial results published to date indicate the once-weekly injection suppresses appetite and may boost metabolism, and some reports describe effects roughly twice those seen with commonly prescribed medicines such as Ozempic. Despite those findings, the drug remains in clinical trials and phase three results are not expected until 2026.

Media reports and social media posts say people are attempting to source Retatrutide through online sellers and informal channels, with some users claiming rapid weight loss of more than three stone in months. The reports also note a dramatic rise in internet searches in the United Kingdom for where to obtain or inject the drug, a spike that coincided with Eli Lilly's announcement of a significant price increase for its approved weight-loss medicine Mounjaro in the U.K.

Clinicians and public-health experts quoted in the reporting described the black market trade as "incredibly risky," warning that products sold outside approved supply chains are often counterfeit, improperly stored, contaminated or incorrectly dosed. Those risks, they say, could lead to serious adverse health effects. The coverage also said that people who buy, possess or supply prescription-only medicines without lawful authority could face criminal penalties, with the report noting potential prison sentences of up to two years for some offences.

Regulatory pathways exist to evaluate safety, efficacy and manufacturing quality, and those processes are still under way for Retatrutide. Until full trial results are reviewed and regulators decide on approval and licensing, clinicians caution that the safety profile and optimal dosing have not been fully established. Experts also note that supervised treatment allows for monitoring of side effects, interactions with other medicines and management of complications—protections that are absent when drugs are sourced illicitly.

Public-health advisers and professional bodies continue to urge people not to obtain or use unregulated products marketed as weight-loss treatments. They emphasize that patients with obesity or weight-related health concerns should seek assessment and treatment through licensed clinicians and established pathways, which can include lifestyle interventions, approved medications and consideration of specialist care when appropriate.

Eli Lilly is continuing clinical development of Retatrutide and has said phase three results are expected in 2026. Regulators and health services have not authorised the drug for general use, and officials encourage anyone who believes they have received an unregulated or counterfeit medicine to seek medical advice promptly and report the source to relevant authorities.